Our services
MAECON provides services to a wide range of stakeholders including MedTech, pharmaceutical industry, healthcare professionals and patients (organizations). These include clinical efficacy trials, consultancy, laboratory testing and educational courses on medication adherence. Read more by clicking on the stakeholder buttons on the right.
MAECON provides services to a wide range of stakeholders including MedTech, pharmaceutical industry, healthcare professionals and patients (organizations). These include clinical efficacy trials, consultancy, laboratory testing and educational courses on medication adherence. Read more by clicking on the stakeholder buttons below.
Our showcases
MAECON performs a variety of medication adherence related projects. These include studies on (pharmaco)epidemiology, usability and bioanalysis to randomized clinical trials of adherence enhancing interventions and digital devices. Further, educational, awareness and intervention development programs are internationally provided. A selection is showcased below.
Development of a real-world registry for digital inhalers (AURORA)
Digital inhalers are currently being assessed in clinical studies and some have recently been introduced on the market. Indeed, digital inhalers could help in management
Usability assessment of a novel smart blister
Recently, an electronic version of the Dosepak® (EDP) has been developed to monitor adherence to tablets, pills or capsules. It consists of a customizable blister
Development of a practical adherence toolkit (TAI Toolkit)
To be most effective, interventions focusing on enhancing adherence should be evidence-based and provided in a personalized manner. To identify personal issues with adherence in
Check our latest news
Economic value of digital inhalers to support adherence
Many innovative digital technologies are promising in supporting medication adherence and clinical decision making. However, they come with certain costs. Whether these costs are offset by clinical and economic benefits is often unknown. To uncover the economic case for digital inhalers, MAECON has performed a cost-effectiveness analysis in patients with
MAECON completes first trial with digital pill bottle in patients with tuberculosis
MAECON is proud to announce that it has completed a new clinical trial studying the effects of a digital pill bottle to support patients with tuberculosis (TB) with medication adherence. The standard treatment regimen for drug-susceptible TB takes 6-9 months and requires daily intake of multiple medications under the observation
MAECON’s impact on international COPD guidelines at Day of Medication Adherence 2022
Today is the Day of Medication Adherence 2022! At MAECON, we are the proud founder of this national day that is now widely celebrated across the Netherlands and beyond. In the end, this day serves to raise awareness on the impact of nonadherence, but also to highlight the solutions we
The team behind MAECON
MAECON works at the University Medical Center Groningen (UMCG) and/or the University of Groningen (UG). The members are independent senior researchers and represent a wide range of sub-specialisms related to medication adherence.
